InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by David Matthew T, Chief Executive Officer. Director active across 1 companies, notably CorMedix Inc.. In total, 6 disclosures have been published. Total volume traded: €25k. The latest transaction was disclosed on 6 December 2021 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations6 total
€3,9811,000 shares@ €3.980632.0% of flow
Common Stock
SEC:0001213900-21-064007·
Ideal exit: 2 Sept 2022 (T+270)
€3,9811,000 shares@ €3.980632.0% of flow
Common Stock
SEC:0001213900-21-064006·
Ideal exit: 2 Sept 2022 (T+270)
€3,9811,000 shares@ €3.98060.0004% mcap16.0% of flow
Common Stock
SEC:0001213900-21-064006:0·
Ideal exit: 2 Sept 2022 (T+270)
€3,9811,000 shares@ €3.98060.0004% mcap16.0% of flow
Common Stock
SEC:0001213900-21-064007:0·
Ideal exit: 2 Sept 2022 (T+270)
€4,4781,000 shares@ €4.478336.0% of flow
Common Stock
SEC:0001213900-21-060724·
Ideal exit: 14 Aug 2022 (T+270)
€4,4781,000 shares@ €4.47830.0005% mcap18.0% of flow
Common Stock
SEC:0001213900-21-060724:0·
Ideal exit: 14 Aug 2022 (T+270)
6 of 6 declarations
About David Matthew T
Matthew T. David serves as Interim CEO and Chief Financial Officer at CorMedix Inc. He oversees the company's financial and strategic operations, ensuring compliance with regulatory standards. Matthew plays a key role in resource management and supporting growth initiatives.
